Just six months after revealing a $10.3 million private placement to back development of a once-shelved therapy, Corbus Pharmaceuticals Holdings Inc. is preparing to submit an investigational new drug application to jump straight into a phase IIa trial of its sole program, an anti-inflammatory therapy it calls Resunab.